Terms ending in 2040
Every in-force patent on Atea Pharmaceuticals, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,874,687 | Highly Active Compounds Against COVID-19 In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,707,480 | Highly Active Compounds Against COVID-19 In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,738,038 | Highly Active Compounds Against COVID-19 In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,813,278 | Highly Active Compounds Against COVID-19 In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,226,429 | Highly Active Compounds Against COVID-19 In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,746,251 | Niran Interfering Drugs for SARS-COV-2 Mutant Therapy In force · Low confidence | Atea Pharmaceuticals, Inc. | In force | Low confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.